Unicycive Therapeutics, Inc. - Common Stock (NQ:UNCY)

3.870 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 21, 2026 Add to My Watchlist

Price and Volume

Volume	94
Open	3.870
Bid (Size)	3.730 (300)
Ask (Size)	4.200 (100)
Prev. Close	3.870
Today's Range	3.870 - 3.870
52wk Range	3.350 - 8.740
Shares Outstanding	14,508,063
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate NDA Resubmission and PDUFA Date of March 25, 2027

October 21, 2026

From Unicycive Therapeutics, Inc.

Via JCN Newswire

Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate New Drug Application Resubmission and PDUFA Date of March 25, 2027

October 21, 2026

Unicycive Therapeutics, Inc. (Nasdaq: UNCY) today announced that the U.S. Food and Drug Administration (FDA) has accepted the resubmission of its New Drug Application (NDA) for oxylanthanum carbonate...

Via B2i Digital

Performance

52-Week Range 55.7% below 52-week high

3.870

3.3552W Low 8.7452W High

1 Week 7.4% below 1-week high

3.351W Low 4.181W High

Unicycive Therapeutics, Inc. - Common Stock (UNCY) traded between $3.35 and $8.74 over the past 52 weeks and last traded at $3.87, 55.7% below its 52-week high. Over the past week it ranged between $3.35 and $4.18.

Past 12 Months

+7.8%

-18.9%

-30.5%

-49.8%

-33.3%

-21.7%

1W +$0.28

1M -$0.90

3M -$1.70

6M -$3.84

YTD -$1.93

1Y -$1.07

UNCY was -21.7% over the past year, -49.8% over six months, -33.3% year to date, +7.8% in the last week.

12 Months vs Market

UNCY

-21.7%

DIA

+12.5%

SPY

+15.2%

QQQ

+18.6%

IWM

+11.9%

Over the past 12 months UNCY returned -21.7% versus DIA (Dow) +12.5%, SPY (S&P 500) +15.2%, QQQ (Nasdaq 100) +18.6% and IWM (Russell 2000) +11.9%.

Volume & Liquidity 0.00× 3-mo avg

Today 94 3-mo avg 863.4K

1.2M

991.5K

863.4K

1.2M

YTD

934.8K

834.5K

UNCY most recently traded 94 shares against a 3-month average daily volume of 863.4K.

More News

Unicycive Therapeutics, Inc. Investors Have Until November 2nd to Contact Bragar Eagel & Squire, P.C. Seeking Lead Plaintiff Role

October 20, 2026

From Bragar Eagel & Squire

Via GlobeNewswire

UNCY DEADLINE: SueWallSt Reminds Unicycive Therapeutics, Inc. Investors of Upcoming Securities Class Action Deadline

October 20, 2026

From SueWallSt

Via GlobeNewswire

UNCY Shareholder Alert: Unicycive Therapeutics, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact Levi & Korsinsky

October 19, 2026

From Levi & Korsinsky, LLP

Via GlobeNewswire

UNCY DEADLINE: Levi & Korsinsky Reminds Unicycive Therapeutics, Inc. Investors of Upcoming Securities Class Action Deadline

October 16, 2026

From Levi & Korsinsky, LLP

Via ACCESS Newswire

Kaplan Fox Alerts Investors to an Upcoming Deadline of November 2, 2026 in the Unicycive Therapeutics, Inc. (NASDAQ: UNCY) Securities Class Action

October 16, 2026

Via NewMediaWire

Kaplan Fox Alerts Unicycive Therapeutics, Inc. (NASDAQ: UNCY) Investors to Seek Leadership in a Securities Fraud Lawsuit by November 2, 2026

October 14, 2026

Via NewMediaWire

UNCY Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Unicycive Therapeutics Securities Lawsuit - Contact SueWallSt

October 13, 2026

From SueWallSt

Via GlobeNewswire

UNCY Shareholder Alert: November 2, 2026 Lead Plaintiff Deadline in Unicycive Therapeutics, Inc. Securities Class Action - Contact Levi & Korsinsky

October 12, 2026

From Levi & Korsinsky, LLP

Via GlobeNewswire

Kaplan Fox & Kilsheimer LLP Alerts Unicycive Therapeutics, Inc. (NASDAQ: UNCY) Investors to the Lead Plaintiff Deadline on November 2, 2026

October 12, 2026

Via NewMediaWire

ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - UNCY

October 11, 2026

From The Rosen Law Firm PA

Via GlobeNewswire

UNCY Investor Alert: Unicycive Therapeutics, Inc. Securities Class Action Notice - Contact Levi & Korsinsky

October 09, 2026

From Levi & Korsinsky, LLP

Via ACCESS Newswire

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - UNCY

October 08, 2026

From The Rosen Law Firm PA

Via GlobeNewswire

UNICYCIVE INVESTOR ALERT: Bragar Eagel & Squire, P.C. Reminds Unicycive Therapeutics, Inc. Investors with Large Losses to Contact the Firm Seeking Lead Plaintiff Role

October 08, 2026

From Bragar Eagel & Squire

Via GlobeNewswire

UNCY SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Unicycive Therapeutics (NASDAQ: UNCY) Investors of Securities Class Action Lawsuit Deadline on November 2, 2026

October 07, 2026

From Faruqi & Faruqi LLP

Via GlobeNewswire

UNCY Stock Drop - Robbins LLP Reminds Investors They May Be Eligible to Lead the Securities Class Action Against Unicycive Therapeutics, Inc.

October 05, 2026

Via Newsfile

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of November 2, 2026 in Unicycive Therapeutics, Inc. Lawsuit - UNCY

October 02, 2026

From Levi & Korsinsky, LLP

Via ACCESS Newswire

Kaplan Fox Class Action Reminder: Unicycive Therapeutics, Inc. (NASDAQ: UNCY) Lead Plaintiff Deadline is November 2, 2026

October 02, 2026

Via NewMediaWire

Unicycive Therapeutics Appoints Meredith Manning to Board of Directors

October 01, 2026

Via B2i Digital

Kaplan Fox Shareholder Alert: Deadline to Lead in the Securities Fraud Lawsuit Against Unicycive Therapeutics, Inc. (NASDAQ: UNCY) is November 2, 2026

September 30, 2026

Via NewMediaWire

Unicycive Therapeutics Announces Resubmission of New Drug Application for Oxylanthanum Carbonate

September 29, 2026

Via B2i Digital

Kaplan Fox Deadline Alert: Unicycive Therapeutics, Inc. (NASDAQ: UNCY) Investors Have Until November 2, 2026 to Seek a Lead Plaintiff Role

September 28, 2026

Via NewMediaWire

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - UNCY

September 25, 2026

From The Rosen Law Firm PA

Via GlobeNewswire

Kaplan Fox Encourages Unicycive Therapeutics, Inc. (NASDAQ: UNCY) Investors to Contact the Firm Before the Deadline on November 2, 2026

September 24, 2026

Via NewMediaWire

Frequently Asked Questions

Is Unicycive Therapeutics, Inc. - Common Stock publicly traded?

Yes, Unicycive Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Unicycive Therapeutics, Inc. - Common Stock trade on?

Unicycive Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Unicycive Therapeutics, Inc. - Common Stock?

The ticker symbol for Unicycive Therapeutics, Inc. - Common Stock is UNCY on the Nasdaq Stock Market

What is the current price of Unicycive Therapeutics, Inc. - Common Stock?

The current price of Unicycive Therapeutics, Inc. - Common Stock is 3.870

When was Unicycive Therapeutics, Inc. - Common Stock last traded?

The last trade of Unicycive Therapeutics, Inc. - Common Stock was at 10/21/26 04:00 PM ET

What is the market capitalization of Unicycive Therapeutics, Inc. - Common Stock?

The market capitalization of Unicycive Therapeutics, Inc. - Common Stock is 56.15M

How many shares of Unicycive Therapeutics, Inc. - Common Stock are outstanding?

Unicycive Therapeutics, Inc. - Common Stock has 56M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.